uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell”

uniQure (NASDAQ:QURE) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research report issued on Thursday.

Several other analysts have also commented on QURE. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, August 20th. Raymond James reaffirmed an “outperform” rating and set a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. The Goldman Sachs Group raised their target price on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of uniQure in a report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, uniQure has a consensus rating of “Hold” and an average target price of $19.50.

uniQure Trading Up 14.7 %

Shares of NASDAQ:QURE opened at $6.47 on Thursday. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The stock has a market cap of $314.11 million, a price-to-earnings ratio of -1.04 and a beta of 0.95. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. The business has a 50-day moving average price of $5.80 and a 200-day moving average price of $5.65.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.08. The firm had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. Equities analysts predict that uniQure will post -4.04 EPS for the current year.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares in the last quarter. BNP Paribas Financial Markets lifted its position in uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after buying an additional 30,054 shares in the last quarter. Privium Fund Management B.V. lifted its position in uniQure by 10.6% during the second quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock worth $2,869,000 after buying an additional 61,501 shares in the last quarter. Acadian Asset Management LLC raised its position in uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares during the period. Finally, Ikarian Capital LLC raised its position in uniQure by 198.1% in the first quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after purchasing an additional 311,768 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.